Madopar (Benserazide Hydrochloride, Levodopa)

Madopar acts on dopaminergic pathways to alleviate motor symptoms associated with Parkinsonian disorders.

• Parkinson's disease: improves tremor, rigidity, bradykinesia and overall motor function.
• Parkinsonian syndrome: reduces motor impairment caused by secondary or atypical Parkinsonism.
• Levodopa‑responsive Parkinsonism: restores dopamine levels to achieve symptomatic control.

• Madopar combines levodopa, a precursor that crosses the blood‑brain barrier and is enzymatically converted to dopamine, with benserazide, a peripheral aromatic L‑amino‑acid decarboxylase inhibitor. Benserazide blocks peripheral conversion of levodopa, increasing its availability to the central nervous system, where levodopa is decarboxylated to dopamine, thereby augmenting deficient dopaminergic neurotransmission in the basal ganglia. The resulting increase in dopamine activity helps normalize motor circuit signaling and reduces the characteristic symptoms of Parkinsonism.

Madopar may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: upset stomach often occurring at treatment initiation.
• Orthostatic hypotension: dizziness or light‑headedness upon standing.
• Insomnia: difficulty falling or staying asleep.
• Dyskinesia: involuntary movements, especially with higher doses.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure drop requiring medical attention.
• Psychosis or hallucinations: visual or auditory disturbances in susceptible patients.
• Allergic reactions: rash, swelling, or anaphylaxis in rare cases.

When prescribing Madopar, clinicians should consider several precautionary measures to optimize safety.

• Dose titration: start with the lowest effective dose and increase gradually to minimize side effects.
• Blood pressure monitoring: watch for orthostatic hypotension, especially in elderly patients.
• Psychiatric assessment: monitor for hallucinations, confusion, or mood changes.
• Drug discontinuation: avoid abrupt cessation to prevent worsening of Parkinsonian symptoms.
• Concomitant medications: review all patient medicines for potential interactions.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Madopar interacts with several agents that can alter its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): may cause hypertensive crisis.
• Antipsychotics (e.g., haloperidol): block dopamine receptors and reduce therapeutic effect.
• Pyridoxine (vitamin B6): enhances peripheral levodopa metabolism, decreasing central availability.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: additive blood‑pressure‑lowering effect may increase dizziness.
• Iron or calcium supplements: can reduce levodopa absorption if taken simultaneously.
• High‑protein meals: compete with levodopa for intestinal transport, potentially diminishing efficacy.